Literature DB >> 9832031

Germline PTEN mutations in Cowden syndrome-like families.

D J Marsh1, P L Dahia, S Caron, J B Kum, I M Frayling, I P Tomlinson, K S Hughes, R A Eeles, S V Hodgson, V A Murday, R Houlston, C Eng.   

Abstract

Cowden syndrome (CS) or multiple hamartoma syndrome (MIM 158350) is an autosomal dominant disorder with an increased risk for breast and thyroid carcinoma. The diagnosis of CS, as operationally defined by the International Cowden Consortium, is made when a patient, or family, has a combination of pathognomonic major and/or minor criteria. The CS gene has recently been identified as PTEN, which maps at 10q23.3 and encodes a dual specificity phosphatase. PTEN appears to function as a tumour suppressor in CS, with between 13-80% of CS families harbouring germline nonsense, missense, and frameshift mutations predicted to disrupt normal PTEN function. To date, only a small number of tumour suppressor genes, including BRCA1, BRCA2, and p53, have been associated with familial breast or breast/ovarian cancer families. Given the involvement of PTEN in CS, we postulated that PTEN was a likely candidate to play a role in families with a "CS-like" phenotype, but not classical CS. To answer these questions, we gathered a series of patients from families who had features reminiscent of CS but did not meet the Consortium Criteria. Using a combination of denaturing gradient gel electrophoresis (DGGE), temporal temperature gel electrophoresis (TTGE), and sequence analysis, we screened 64 unrelated CS-like subjects for germline mutations in PTEN. A single male with follicular thyroid carcinoma from one of these 64 (2%) CS-like families harboured a germline point mutation, c.209T-->C. This mutation occurred at the last nucleotide of exon 3 and within a region homologous to the cytoskeletal proteins tensin and auxilin. We conclude that germline PTEN mutations play a relatively minor role in CS-like families. In addition, our data would suggest that, for the most part, the strict International Cowden Consortium operational diagnostic criteria for CS are quite robust and should remain in place.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832031      PMCID: PMC1051477          DOI: 10.1136/jmg.35.11.881

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  39 in total

1.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.

Authors:  M R Nelen; W C van Staveren; E A Peeters; M B Hassel; R J Gorlin; H Hamm; C F Lindboe; J P Fryns; R H Sijmons; D G Woods; E C Mariman; G W Padberg; H Kremer
Journal:  Hum Mol Genet       Date:  1997-08       Impact factor: 6.150

3.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

Authors:  D J Marsh; P L Dahia; Z Zheng; D Liaw; R Parsons; R J Gorlin; C Eng
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

Review 4.  From bench to bedside... but when?

Authors:  C Eng
Journal:  Genome Res       Date:  1997-07       Impact factor: 9.043

5.  TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

Authors:  D M Li; H Sun
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

6.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

7.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

8.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

Authors:  P Guldberg; P thor Straten; A Birck; V Ahrenkiel; A F Kirkin; J Zeuthen
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

9.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

Authors:  E Rhei; L Kang; F Bogomolniy; M G Federici; P I Borgen; J Boyd
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

10.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

View more
  34 in total

Review 1.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

Authors:  Kristi L Bennett; Jessica Mester; Charis Eng
Journal:  JAMA       Date:  2010-12-22       Impact factor: 56.272

3.  Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Authors:  Joanne Ngeow; Jessica Mester; Lisa A Rybicki; Ying Ni; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

4.  PTEN C-terminal deletion causes genomic instability and tumor development.

Authors:  Zhuo Sun; Chuanxin Huang; Jinxue He; Kristy L Lamb; Xi Kang; Tingting Gu; Wen Hong Shen; Yuxin Yin
Journal:  Cell Rep       Date:  2014-02-20       Impact factor: 9.423

5.  Male breast cancer in Cowden syndrome patients with germline PTEN mutations.

Authors:  J D Fackenthal; D J Marsh; A L Richardson; S A Cummings; C Eng; B G Robinson; O I Olopade
Journal:  J Med Genet       Date:  2001-03       Impact factor: 6.318

6.  Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers.

Authors:  I De Vivo; D M Gertig; S Nagase; S E Hankinson; R O'Brien; F E Speizer; R Parsons; D J Hunter
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

7.  Vitamin E protects against lipid peroxidation and rescues tumorigenic phenotypes in cowden/cowden-like patient-derived lymphoblast cells with germline SDHx variants.

Authors:  Ying Ni; Charis Eng
Journal:  Clin Cancer Res       Date:  2012-07-24       Impact factor: 12.531

8.  Frequency of germline PTEN mutations in differentiated thyroid cancer.

Authors:  Rebecca Nagy; Shireen Ganapathi; Ilene Comeras; Charissa Peterson; Mohammed Orloff; Kyle Porter; Charis Eng; Matthew D Ringel; Richard T Kloos
Journal:  Thyroid       Date:  2011-03-21       Impact factor: 6.568

9.  Rapid mutation scanning of genes associated with familial cancer syndromes using denaturing high-performance liquid chromatography.

Authors:  D J Marsh; G Theodosopoulos; V Howell; A L Richardson; D E Benn; A L Proos; C Eng; B G Robinson
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

10.  Germline PTEN mutations are rare and highly penetrant.

Authors:  Cecilie F Rustad; Merete Bjørnslett; Ketil R Heimdal; Lovise Mæhle; Jaran Apold; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.